The immune response to a model antigen associated with PLG microparticles prepared using different surfactants

Vaccine

Volumn 15, Issue 17-18, 1997, Pages 1888-1897

  Rafati, H ^a   Lavelle, E C ^b   Coombes, A G A ^b   Stolnik, S ^b   Holland, J ^b   Davis, S S ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Daro Pakhsh Pharmaceuticals plc   (Iran)

Author keywords

Immune response; Ovalbumin; PLG microparticles; Surface charge; Surfactant

Indexed keywords

BILE SALT; MACROGOL DERIVATIVE; POLYGLACTIN; POLYVINYL ALCOHOL; SURFACTANT;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; FEMALE; HYDROPHOBICITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURFACE CHARGE; ZETA POTENTIAL;

ANIMALS; ANTIGENS; BILE ACIDS AND SALTS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; EMULSIONS; FEMALE; GLYCEROL; IMMUNOGLOBULIN G; LACTIC ACID; MICE; MICE, INBRED BALB C; OVALBUMIN; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; POLYVINYL ALCOHOL; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS;

EID: 0030735939     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00134-5     Document Type: Article

References (36)

1. Khan, M.Z.I., Optebeeck, J.P. and Tucker, I.G. Immuno-potentiation and delivery systems for antigens for single-step immunisation. Recent Trends Progr. Pharm. Res. 1994, 11, 2-11.
2. Gupta, R.K. and Siber, G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995, 13, 1263-1276.
3. Morris, W., Steinhoff, M.C. and Russell, P.K. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994, 12, 5-11.
4. Steineker, F., Kersten, G., Bloois, L.V., Crommelin, D.J.A., Hem, S.L., Lower, J. and Kreuter, J. Comparison of 24 different adjuvants for inactivated HIV-split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 1995, 13, 45-53.
5. Hunter, R., Strickland, F. and Kezdy, F. The adjuvant activity of nonionic block polymer surfactants I. the role of hydrophile-lipophile balance. J. Immunol. 1981, 127, 1244-1250.
6. O'Hagan, D.T., Rahman, D., McGee, J.P., Jeffery, H., Davies, M.C., Williams, P. and Davis, S.S. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991, 73, 239-242.
7. Agondo, M.T. and Lambert, P.H. Controlled release vaccines - biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology 1992, 184, 113-125.
8. Alonso, M.J., Cohen, S., Park, T.G., Gupta, R.K., Siber, G.R. and Langer, R. Determination of release rate of tetanus vaccine from polyester microspheres. Pharm. Res. 1993, 10, 945-953.
9. O'Hagan, D.T. Novel Delivery Systems for Oral Vaccines. CRC Press, Boca Raton, 1994
10. O'Hagan, D.T., Jeffery, H. and Davis, S.S. Long-term antibody response in mice following subcautaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11, 965-969.
11. Reid, R.H., Boedeker, E.C., McQueen, C.E., Avis, D., Tseng, L.-Y., Kodak, J., Sau, K., Willhelmsen, C.L., Nellore, R., Dalal, P. and Bhagat, H.R. Preclinical evaluation of microencapsulated CFA/II oral vaccine against enterotoxin E. coli. Vaccine 1993, 11, 159-166.
12. Uchida, T., Goto, S.H. and Foster, T.P. Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation. J. Pharm. Pharmacol. 1994, 47, 556-560.
13. Coombes, A.G.A., Lavelle, E.C., Jenkins, P.G. and Davis, S.S. Single dose polymeric microparticulate vaccine delivery systems: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 1996, 14, 1429-1438.
14. Illum, L., Davis, S.S., Muller, R.H., Mak, E. and West, P. The organ distribution and circulation time of intravenously injected colloid carriers sterically stabilised with block copolymer-poloxamine 908. Life Sci. 1987, 40, 1553-1560.
15. Alleman, E., Gurny, R. and Doelker, E. Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 1993, 39, 173-191.
16. Troster, S.D. and Kreuter, J. Influence of the surface-properties of low contact-angle surfactants on the body distribution of C-14 poly(methyl methacrylate) nanoparticles. J. Microencap. 1992, 9, 19-28.
17. Eldridge, J.H., Stass, J.K., Tice, T.R. and Gilley, R.M. Biodegradable poly(D,L-lactide-co-glycolide) microspheres. Res. Immun. 1992, 143, 557-563.
18. Kreuter, J., Liehl, E., Berg, U., Soliva, M. and Speiser, P.P. Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants. Vaccine 1988, 6, 253-256.
19. Hunter, R., Olsen, M. and Buynitzky, S. Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody. Vaccine 1991, 9, 250-256.
20. Takayama, K., Olsen, M., Datta, P. and Hunter, R. Adjuvant activity of nonionic block copolymers. V. modulation of antibody isotype by lipopolysaccharides, lipid A and precursors. Vaccine 1991, 9, 257-265.
21. Alpar, H.O. and Almeida, A.J. Identification of some of the physicochemical characteristics of microspheres which influence the induction of the immune response following mucosal delivery. Eur. J. Pharm. Biopharm. 1994, 40, 198-202.
22. Fessi, H., Poisieux, F., Deviessaguet, J.Ph., Ammoury, N. and Benita, S. Nanoparticle formulation by polymer deposition following solvent displacement. Int. J. Pharm. 1989, 55, R1-R5.
23. Stolnik, S., Davies, M.C., Illum, L., Davis, S.S., Boustta, M. and Vert, M. The preparation of sub-200 nm biodegradable colloidal particles from poly(β-malic acid-co-benzyl maleate) copolymer and their surface modification with poloxamer and poloxamine surfactants. J. Control. Rel. 1994, 30, 57-67.
24. Thompson, S. and Coombes, A.G.A. Unpublished work
25. Rafati, H., Coombes, A.G.A., Adler, J., Holland, J. and Davis, S.S. Protein-loaded poly(D,L-lactide-co-glycolide) microparticles for oral administration: formulation, structural and release characteristics. J. Control. Rel. 1997, 43, 89-102.
26. Challacombe, S.J., Rahman, D., Jeffery, H., Davis, S.S. and O'Hagan, DT. Enhanced sectretory IgA and systemic IgG antibody response after oral immunization with biodegradable microparticles containing antigen. Immunology 1992, 76, 164-168.
27. Eldridge, J.H., Stass, J.K., Meulbroek, J.A., Tice, T.R. and Gilley, R.M. Biodegradable and biocompatibale poly(D,L-lactide-co-glycolide) microspheres as an adjuvant for Staphylococcal enterotoxin-B toxoid which enhances the level of toxin-neutralizing antibodies. Infec. Immun. 1991, 59, 2978-2986.
28. Kreuter, J., Mauler, R., Gruschkau, H. and Speiser, P.P. The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp. Cell Biol. 1976, 44, 12-19
29. Tang, L. and Eaton, J.W. Mechanism of acute inflammatory response to biomaterials. Cell and Materials 1994, 4, 429-436.
30. Verrechia, T., Huve, P., Bazile, D., Veillard, M., Spenlehauer, G. and Couvreur, P. Adsorption/desorption of human serum albumin at the surface of poly(lactic acid) nanoparticles prepared by a solvent evaporation process. J. Biomed. Mater. Res. 1993, 27, 1019-1028.
31. Koosha, F., Muller, R.H., Davis, S.S. and Davies, M.C. The surface chemical structure of poly(B-hydroxybutyrate) microparticles produced by solvent evaporation process. J. Control. Rel. 1989, 9, 149-157.
32. Coombes, A.G. et al. Resorbable polymeric microspheres for drug delivery - production and simultaneous surface modification using PEO-PPPO surfactants. Biomaterials 1994, 15, 673-680.
33. Carrio, A., Schwach, G., Coudane, J. and Vert, M. Preparation and degradation of surfactant-free PLGA microspheres. J. Control. Rel. 1995, 37, 113-121.
34. Washington, C. Particle Size Analysis in Pharmaceutics and other Industries. Theory and Practice, Chapter 7. Ellis Horwood, Chichester, 1992
35. Illum, L., Jacobsen, L.O., Muller, R.H., Mak, E. and Davis, S.S. Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 1987, 8, 113-117.
36. Gizurarson, S., Jonsdottir, V.M. and Heron, I. Internasal administration of diphtheria toxoid. Selecting antibody isotypes using formulations having various lipophilic characteristics. Vaccine 1995, 13, 617-621.